Dendritic Cells Release HLA-B-associated Transcript-3 Positive Exosomes to Regulate Natural Killer Function

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2008 Oct 15

PMID 18852879

Citations 138

Authors

Venkateswara Rao Simhadri

Katrin S Reiners

Hinrich P Hansen

Daniela Topolar

Vijaya Lakshmi Simhadri

Klaus Nohroudi

Thomas A Kufer

Andreas Engert

Elke Pogge von Strandmann

Affiliations

Soon will be listed here.

Abstract

NKp30, a natural cytotoxicity receptor expressed on NK cells is critically involved in direct cytotoxicity against various tumor cells and directs both maturation and selective killing of dendritic cells. Recently the intracellular protein BAT3, which is involved in DNA damage induced apoptosis, was identified as a ligand for NKp30. However, the mechanisms underlying the exposure of the intracellular ligand BAT3 to surface NKp30 and its role in NK-DC cross talk remained elusive. Electron microscopy and flow cytometry demonstrate that exosomes released from 293T cells and iDCs express BAT3 on the surface and are recognized by NKp30-Ig. Overexpression and depletion of BAT3 in 293T cells directly correlates with the exosomal expression level and the activation of NK cell-mediated cytokine release. Furthermore, the NKp30-mediated NK/DC cross talk resulting either in iDC killing or maturation was BAT3-dependent. Taken together this puts forward a new model for the activation of NK cells through intracellular signals that are released via exosomes from accessory cells. The manipulation of the exosomal regulation may offer a novel strategy to induce tumor immunity or inhibit autoimmune diseases caused by NK cell-activation.

Citing Articles

Prospect of extracellular vesicles in tumor immunotherapy.

Xia W, Tan Y, Liu Y, Xie N, Zhu H Front Immunol. 2025; 16:1525052.

PMID: 40078996 PMC: 11897508. DOI: 10.3389/fimmu.2025.1525052.

Potential and development of cellular vesicle vaccines in cancer immunotherapy.

Zhao W, Li X, Guan J, Yan S, Teng L, Sun X Discov Oncol. 2025; 16(1):48.

PMID: 39812959 PMC: 11735706. DOI: 10.1007/s12672-025-01781-3.

Harnessing the power of exosomes for diagnosis, prognosis, and treatment of hematological malignancies.

Mohseni A, Salehi F, Rostami S, Hadiloo K, Hashemi M, Baridjavadi Z Stem Cell Res Ther. 2025; 16(1):6.

PMID: 39773361 PMC: 11708188. DOI: 10.1186/s13287-024-04125-0.

Exosomes in infectious diseases: insights into leishmaniasis pathogenesis, immune modulation, and therapeutic potential.

Abida , Alhuthali H, Alshehri J, Alkathiri A, Almaghrabi R, Alsaeed S Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39702600 DOI: 10.1007/s00210-024-03702-7.

Tissue-resident natural killer cells support survival in pancreatic cancer through promotion of cDC1-CD8 T activity.

Go S, Demetriou C, Valenzano G, Hughes S, Lanfredini S, Ferry H Elife. 2024; 13.

PMID: 39656086 PMC: 11630822. DOI: 10.7554/eLife.92672.

References

Yu X, Harris S, Levine A . The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res. 2006; 66(9):4795-801. DOI: 10.1158/0008-5472.CAN-05-4579. View

Bryceson Y, March M, Ljunggren H, Long E . Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2005; 107(1):159-66. PMC: 1895346. DOI: 10.1182/blood-2005-04-1351. View

Garg A, Barnes P, Porgador A, Roy S, Wu S, Nanda J . Vimentin expressed on Mycobacterium tuberculosis-infected human monocytes is involved in binding to the NKp46 receptor. J Immunol. 2006; 177(9):6192-8. DOI: 10.4049/jimmunol.177.9.6192. View

North J, Bakhsh I, Marden C, Pittman H, Addison E, Navarrete C . Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation. J Immunol. 2006; 178(1):85-94. DOI: 10.4049/jimmunol.178.1.85. View

Sasaki T, Gan E, Wakeham A, Kornbluth S, Mak T, Okada H . HLA-B-associated transcript 3 (Bat3)/Scythe is essential for p300-mediated acetylation of p53. Genes Dev. 2007; 21(7):848-61. PMC: 1838535. DOI: 10.1101/gad.1534107. View

Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A . Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity. 2007; 26(4):503-17. PMC: 2084390. DOI: 10.1016/j.immuni.2007.03.006. View

Ivanov I, Lo K, Hawthorn L, Cowell J, Ionov Y . Identifying candidate colon cancer tumor suppressor genes using inhibition of nonsense-mediated mRNA decay in colon cancer cells. Oncogene. 2006; 26(20):2873-84. DOI: 10.1038/sj.onc.1210098. View

Kaiser B, Yim D, Chow I, Gonzalez S, Dai Z, Mann H . Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature. 2007; 447(7143):482-6. DOI: 10.1038/nature05768. View

Elsner L, Muppala V, Gehrmann M, Lozano J, Malzahn D, Bickeboller H . The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands. J Immunol. 2007; 179(8):5523-33. DOI: 10.4049/jimmunol.179.8.5523. View

10.

Byrd A, Hoffmann S, Jarahian M, Momburg F, Watzl C . Expression analysis of the ligands for the Natural Killer cell receptors NKp30 and NKp44. PLoS One. 2007; 2(12):e1339. PMC: 2129109. DOI: 10.1371/journal.pone.0001339. View

11.

Hershkovitz O, Jarahian M, Zilka A, Bar-Ilan A, Landau G, Jivov S . Altered glycosylation of recombinant NKp30 hampers binding to heparan sulfate: a lesson for the use of recombinant immunoreceptors as an immunological tool. Glycobiology. 2007; 18(1):28-41. DOI: 10.1093/glycob/cwm125. View

12.

Pogge von Strandmann E, Simhadri V, von Tresckow B, Sasse S, Reiners K, Hansen H . Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity. 2007; 27(6):965-74. DOI: 10.1016/j.immuni.2007.10.010. View

13.

Desmots F, Russell H, Michel D, McKinnon P . Scythe regulates apoptosis-inducing factor stability during endoplasmic reticulum stress-induced apoptosis. J Biol Chem. 2007; 283(6):3264-3271. DOI: 10.1074/jbc.M706419200. View

14.

Gehrmann M, Liebisch G, Schmitz G, Anderson R, Steinem C, De Maio A . Tumor-specific Hsp70 plasma membrane localization is enabled by the glycosphingolipid Gb3. PLoS One. 2008; 3(4):e1925. PMC: 2271151. DOI: 10.1371/journal.pone.0001925. View

15.

Bryceson Y, Long E . Line of attack: NK cell specificity and integration of signals. Curr Opin Immunol. 2008; 20(3):344-52. PMC: 2564616. DOI: 10.1016/j.coi.2008.03.005. View

16.

Lespagnol A, Duflaut D, Beekman C, Blanc L, Fiucci G, Marine J . Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice. Cell Death Differ. 2008; 15(11):1723-33. DOI: 10.1038/cdd.2008.104. View

17.

Thress K, Song J, Morimoto R, Kornbluth S . Reversible inhibition of Hsp70 chaperone function by Scythe and Reaper. EMBO J. 2001; 20(5):1033-41. PMC: 145500. DOI: 10.1093/emboj/20.5.1033. View

18.

Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C . Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med. 2001; 7(3):297-303. DOI: 10.1038/85438. View

19.

Ferlazzo G, Tsang M, Moretta L, Melioli G, Steinman R, Munz C . Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med. 2002; 195(3):343-51. PMC: 2193591. DOI: 10.1084/jem.20011149. View

20.

Andre F, Schartz N, Movassagh M, Flament C, Pautier P, Morice P . Malignant effusions and immunogenic tumour-derived exosomes. Lancet. 2002; 360(9329):295-305. DOI: 10.1016/S0140-6736(02)09552-1. View